Publications Office of the EU
Finland-Helsinki: Pharmaceutical products - EU tenders
DisplayCustomHeader
Procurement Detail Actions Portlet
OP Portal - Procurement - Details

Finland-Helsinki: Pharmaceutical products

  • Awarded
    23/03/2022
  • Today
    10/08/2026
Status
Awarded
Type of contract
Supplies
Subject for Renewal
No
Buyer
Helsingin ja Uudenmaan Sairaanhoitopiirin kuntayhtymä
Place of performance
NUTS code: FI1B Helsinki-Uusimaa
Location of buyer
NUTS code: FI1B Helsinki-Uusimaa
Business sector (Main CPV)
33600000 Pharmaceutical products
Total estimated contract value (excluding VAT)
Not available
Total final contract value (excluding VAT)
3,000,000.00 EUR
Tender reference number
§ 26 23.3.2022
Description

Serliponaasi alfa -valmisteen (Brineura 150 mg infuusioneste, liuos) hankinta Helsingin ja Uudenmaan sairaanhoitopiirissä valmisteyhteenvedon mukaiseen käyttöön 12.4.2022– 31.12.2023 sekä mahdollisen optiovuoden (1.1.-31.12.2024) ajan. Brineura on tarkoitettu neuronaalisen seroidilipofuskinoosi tyyppi 2:n (CLN2), toiselta nimeltään tripeptidyylipeptidaasi 1:n (TPP1) puute, hoitoon.

Submission Method
Not available
Tenders may be submitted
Not applicable
Information about a public contract, a framework agreement or a dynamic purchasing system (DPS)
Not available
Conditions for opening tenders (date)
Not available
Place of performance
Award method
Not specified
Estimated value
Not available
Final contracted value
3,000,000.00 EUR
Award of contract
Official name: BioMarin International Limited
Postal address:
Town: Dublin
Postal code:
Country: IRL
Prior information
Contract
Award
Footnote - legal notice

This content published on this page is meant purely as an additional service and has no legal effect. The Union's institutions do not assume any liability for its contents. The official versions of the relevant tendering notices are those published in the Supplement of Official Journal of the European Union and available in TED. Those official texts are directly accessible through the links embedded in this page. For more information please see Public Procurement Explainability and Liability notice.